BRAIN Biotech AG
XETRA:BNN
BRAIN Biotech AG
Cost of Revenue
BRAIN Biotech AG
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BRAIN Biotech AG
XETRA:BNN
|
Cost of Revenue
-€24.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Wacker Chemie AG
XETRA:WCH
|
Cost of Revenue
-€5.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
Evonik Industries AG
XETRA:EVK
|
Cost of Revenue
-€11.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
Covestro AG
XETRA:1COV
|
Cost of Revenue
-€12.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
AlzChem Group AG
XETRA:ACT
|
Cost of Revenue
-€232.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Symrise AG
XETRA:SY1
|
Cost of Revenue
-€3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
See Also
What is BRAIN Biotech AG's Cost of Revenue?
Cost of Revenue
-24.2m
EUR
Based on the financial report for Dec 31, 2023, BRAIN Biotech AG's Cost of Revenue amounts to -24.2m EUR.
What is BRAIN Biotech AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-6%
Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for BRAIN Biotech AG have been -14% over the past three years , -6% over the past five years .